Updated
September 28th, 2019

Rwanda Launches Ebola Vaccination Campaign for 7,949 Workers

Ebola vaccine V920 (rVSV-ZEBOV) to be deployed in Rwanda

map of central africa

The Rwanda Ministry of Health announced it will launch vaccination of healthcare and frontline health workers to protect them from the Ebola Virus Disease (EVD). 

About 7,949 healthcare workers and frontline workers in Rwanda will receive Merck’s v920 (rVSV-ZEBOV) experimental Ebola Zaire vaccine. 

The Rwandan Minister of Health, Dr. Diane Gashumba said in a press release, "This vaccine assures readiness as far as Ebola preparedness is concerned. The vaccine will not target the general population, but will focus on frontline health workers who may be at high risk in case of Ebola outbreak." 

Though not yet commercially licensed but as recommended by the Strategic Advisory Group of Experts on Immunization, the vaccine is being provided for "compassionate use" to efficiently tackle the ongoing Ebola Virus Disease in North Kivu province of DRC. 

More than 100,000 people have already been vaccinated with v920 in DRC 

This vaccination effort is scheduled to begin on Monday, April 15, 2019, in Rubavu and other Rwanda districts in high-risk zones located near the Democratic Republic of Congo (DRC). 

The African countries Uganda, Burundi, and South Sudan also boarder the DRC.

The Ebola outbreak in the DRC continues to report negative news. 

As of April 7, 2019, the cumulative number of Ebola cases has reached 1,154, of which 1,088 are confirmed and 66 are probable, since the beginning of the epidemic in August 2018.

Sponsored Links:

Unfortunately, there were 731 Ebola-related deaths confirmed.

Recent Ebola vaccine news:

  • On March 29th, the U.S. Food and Drug Administration (FDA) began supporting the development of a drug candidate, Remdesivir, for treating Ebola virus infections. 
  • On March 23rd, the Ebola vaccine candidate Inovio INO-4201 reported 96% seroconverted after 3 doses.
  • On February 23rd, Ebola vaccine candidate EBOV-GP reported formulations were equally immunogenic in liquid and lyophilized forms. 
  • On February 20th, Merck’s v920 Ebola vaccine candidate became available to pregnant and lactating women in the Democratic Republic of Congo. 

To notify USA residents of the ongoing Ebola outbreak, the Centers for Disease Control and Prevention (CDC) expanded its Level 2 Travel Alert regarding the Ebola Zaire outbreak in the North Kivu and Ituri provinces of the DRC.

This expanded Travel Alert, Practice Enhanced Precautions, published on March 6, 2019, says ‘travelers to the DRC could be infected with Ebola if they come into contact with an infected person’s blood or other body fluids.

Additionally, the CDC says ‘travelers leaving the Ebola outbreak area may be subject to travel restrictions or monitoring by ministries of health in other countries and should check in advance for any requirements.’

And, on March 29th, the CDC issued a measles-related Travel Alert for the DRC.

This means travelers to the DRC should be vaccinated against measles and other diseases. 

International travelers can easily schedule a pre-trip vaccine and medication counseling session with a local healthcare provider at Vax-Before-Travel.